-
今开：--
昨收：--
-
今日区间：--
52周区间：--
-
成交量：--
成交额：--
-
市 值：--
市盈率：--
-
振幅：
每股收益：
成交量
董事会
- Wu Bin Pan
- Wu Bin Pan is the founder of Crown Bioscience International, founded in 2006. He was also the founder of Crown Bioscience, Inc., founded in 2006, where he held the title of Chief Operating Officer, EVP & China President from 2006 to 2011. In 2012, Dr. Pan founded Suzhou Connect Biopharma Co. Ltd., where he currently serves as Chairman & President. He also founded Connect Biopharma Holdings Ltd. in 2012 and holds the title of Director. Dr. Pan's current job is as a Director at Connect Biopharma HongKong Ltd. He previously worked as a Principal at Terragen Discovery, Inc. and as Vice President at Shenzhen Yuanxing Biomedical Technology Co., Ltd. from 2000 to 2006. Dr. Pan's education includes a doctorate from the University of Sussex in 1994, an MBA from Tsinghua University in 2010, and an undergraduate degree from Sun Yat-Sen University in 1985.
-
- Zheng Wei
- Zheng Wei is the founder of Connect Biopharma Holdings Ltd., which was founded in 2015. He is currently the Chief Executive Officer & Director at Connect Biopharm LLC. Dr. Wei previously worked as the Director-Immunology at Arena Pharmaceuticals, Inc. from 2007 to 2011. He holds a doctorate degree from the University of California, Davis, and an undergraduate degree from South China Normal University.
-
- Wu Bin Pan
- Wu Bin Pan is the founder of Crown Bioscience International, founded in 2006. He was also the founder of Crown Bioscience, Inc., founded in 2006, where he held the title of Chief Operating Officer, EVP & China President from 2006 to 2011. In 2012, Dr. Pan founded Suzhou Connect Biopharma Co. Ltd., where he currently serves as Chairman & President. He also founded Connect Biopharma Holdings Ltd. in 2012 and holds the title of Director. Dr. Pan's current job is as a Director at Connect Biopharma HongKong Ltd. He previously worked as a Principal at Terragen Discovery, Inc. and as Vice President at Shenzhen Yuanxing Biomedical Technology Co., Ltd. from 2000 to 2006. Dr. Pan's education includes a doctorate from the University of Sussex in 1994, an MBA from Tsinghua University in 2010, and an undergraduate degree from Sun Yat-Sen University in 1985.
-
- Karen J. Wilson
- Karen J. Wilson founded GV Partners LLC in 2004, where she worked as CEO from 2004 to 2007. Ms. Wilson also currently works at Elicio Therapeutics, Inc. (United States), as Director, LAVA Therapeutics NV, as Independent Non-Executive Director from 2021, Suzhou Connect Biopharma Co. Ltd., as Director from 2020, and various other companies. Ms. Wilson also formerly worked at The World Economic Forum USA, Inc., as Executive Director & Associate Member of the Board from 1999 to 2001, Index Venture Management (US), Inc., as Director from 2001 to 2004, Harvard Business School, as Executive Director & Global Initiative from 1993 to 1999, and various other companies. Ms. Wilson received her undergraduate degree in 1986 from the University of California, Berkeley and Masters Business Admin degree from Harvard Business School.
-
- Kleanthis G. Xanthopoulos
- Kleanthis G. Xanthopoulos is the founder of Anadys Pharmaceuticals, Inc. (founded in 1992), SENT , Inc. (California) (founded in 2007), and SENT Labs (founded in 2007). He held the title of Director at Anadys Pharmaceuticals, Inc. from 2006 to 2011. He is also the founder of Shoreline Biosciences, Inc. Dr. Xanthopoulos's current jobs include Chairman at Stork Capital SARL (since 2020), Chairman at Connect Biopharma Holdings Ltd. (since 2020), Director at Irras AB (since 2015), Director at Suzhou Connect Biopharma Co. Ltd. (since 2020), President at Helios, Inc., Member-Executive Board at BIOCOM (since 2014), and Managing Partner at Vandel Group LLC. His former jobs include President, Chief Executive Officer & Director at Regulus Therapeutics, Inc. (2015), Chairman at Apricus Biosciences, Inc. (2013-2019), Chairman at Bioniz Therapeutics, Inc. (2016), Director at ZP Opco, Inc., Director at Biotechnology Innovation Organization, Director at J.E.M. Capital, Inc. (2013-2014), Managing Director at Enterprise Partners Venture Capital (2007), Director at Odyssey Thera, Inc., Director at Aspirus, Inc., Director at Laboratori Derivati Organici SpA (2016-2017), Independent Director at Zosano Pharma Corp. (2013-2021), Senior Vice President at Ionis Pharmaceuticals, Inc., and Vice President-Genomics & Molecular Biology at Aurora Biosciences Corp. (1997-2000). He also served as an Associate Professor at Karolinska Institutet and Section Head at the National Human Genome Research Institute (1995-1997). Dr. Xanthopoulos's education includes a doctorate degree from the University of Stockholm (1986), a graduate degree from the University of Stockholm (1982), and an undergraduate degree from Aristotle University of Thessaloniki (1980). Dr. Xanthopoulos is also the founder of Shoreline Biosciences, Inc...
-
- Kleanthis G. Xanthopoulos
- Kleanthis G. Xanthopoulos is the founder of Anadys Pharmaceuticals, Inc. (founded in 1992), SENT , Inc. (California) (founded in 2007), and SENT Labs (founded in 2007). He held the title of Director at Anadys Pharmaceuticals, Inc. from 2006 to 2011. He is also the founder of Shoreline Biosciences, Inc. Dr. Xanthopoulos's current jobs include Chairman at Stork Capital SARL (since 2020), Chairman at Connect Biopharma Holdings Ltd. (since 2020), Director at Irras AB (since 2015), Director at Suzhou Connect Biopharma Co. Ltd. (since 2020), President at Helios, Inc., Member-Executive Board at BIOCOM (since 2014), and Managing Partner at Vandel Group LLC. His former jobs include President, Chief Executive Officer & Director at Regulus Therapeutics, Inc. (2015), Chairman at Apricus Biosciences, Inc. (2013-2019), Chairman at Bioniz Therapeutics, Inc. (2016), Director at ZP Opco, Inc., Director at Biotechnology Innovation Organization, Director at J.E.M. Capital, Inc. (2013-2014), Managing Director at Enterprise Partners Venture Capital (2007), Director at Odyssey Thera, Inc., Director at Aspirus, Inc., Director at Laboratori Derivati Organici SpA (2016-2017), Independent Director at Zosano Pharma Corp. (2013-2021), Senior Vice President at Ionis Pharmaceuticals, Inc., and Vice President-Genomics & Molecular Biology at Aurora Biosciences Corp. (1997-2000). He also served as an Associate Professor at Karolinska Institutet and Section Head at the National Human Genome Research Institute (1995-1997). Dr. Xanthopoulos's education includes a doctorate degree from the University of Stockholm (1986), a graduate degree from the University of Stockholm (1982), and an undergraduate degree from Aristotle University of Thessaloniki (1980). Dr. Xanthopoulos is also the founder of Shoreline Biosciences, Inc...
-
- Jean I. Liu
- Jean I. Liu is currently serving as a Director at Suzhou Connect Biopharma Co. Ltd. and as an Independent Director at Erasca, Inc., Connect Biopharma Holdings Ltd., and The State Bar of California. Previously, she held positions as a Director at Cascadian Therapeutics LLC, Secretary, Senior Vice President & General Counsel at DURECT Corp., Secretary & Chief Legal Officer at Seagen Inc., Secretary, Vice President & General Counsel at Halozyme Therapeutics, Inc., Attorney at Pillsbury Madison & Sutro LLP, and Attorney at Venture Law Group. Ms. Liu obtained a graduate degree from The Trustees of Columbia University in The City of New York and Stanford University, and an undergraduate degree from the University of Michigan.
-
- Zuie Chin Huang
- Zuie Chin Huang founded Orion Biotech Opportunities Corp. in 2021, where he is working as Chief Executive Officer & Director from 2021. Mr. Huang also founded Zai Lab Ltd., Legend Biotech Corp., and TriArm Therapeutics (Taiwan) Ltd., where he is working as Chairman. Mr. Huang also currently works at Wuhan Kindstar Co. Ltd., as Chairman, Eden Biologics, Inc., as Co-Chairman, Tactiva Therapeutics LLC, as Chairman, and various other companies. Mr. Huang also formerly worked at Windtree Therapeutics, Inc., as Chairman from 2019 to 2023, Alaunos Therapeutics, Inc., as Executive Chairman from 2021 to 2023, Ceptaris Therapeutics, Inc., as Director, and various other companies. Mr. Huang received his graduate degree from Stanford University, undergraduate degree in 1988 from the University of California, Berkeley, and Masters Business Admin degree in 1992 from Stanford Graduate School of Business.
-
- Barry D. Quart
- Dr. Barry D. Quart is an Independent Director at Kiniksa Pharmaceuticals International Plc, a Chief Executive Officer & Director at Connect Biopharma Holdings Ltd. and an Independent Director at Kiniksa Pharmaceuticals Ltd. He is on the Board of Directors at Kiniksa Pharmaceuticals International Plc, Connect Biopharma Holdings Ltd., Kiniksa Pharmaceuticals Ltd., Kiniksa Pharmaceuticals Corp. and NeuroGenetic Pharmaceuticals, Inc. Dr. Quart was previously employed as a Chairman & Chief Executive Officer by Heron Therapeutics, Inc., an Independent Director by Synageva BioPharma Corp., a President, Chief Executive Officer & Director by Ardea Biosciences, Inc., a President by PS Pharmaceuticals, Inc., a President-Research & Development by Agouron Pharmaceuticals LLC, a Director, SVP-Global Research & Development by Pfizer (La Jolla), and a Senior VP-Pfizer Global Research & Development by Pfizer Inc. He also served on the board at Trimeris, Inc. He received his doctorate degree from The University of California, San Francisco.
-
- James A. Schoeneck
- James A. Schoeneck currently works at FibroGen, Inc., as Chairman from 2020, Connect Biopharma Holdings Ltd., as Independent Director from 2025, Calidi Biotherapeutics (Nevada), Inc., as Director from 2020, and Calidi Biotherapeutics, Inc., as Independent Director from 2020. Mr. Schoeneck also formerly worked at Assertio Therapeutics, Inc., as President, Chief Executive Officer & Director from 2011 to 2017, BrainCells, Inc., as Chief Executive Officer from 2005 to 2011, ActivX Biosciences, Inc., as Chief Executive Officer from 2003 to 2004, AnaptysBio, Inc., as Director from 2015 to 2018, Rhone-Poulenc Rorer, Inc., as Director-Marketing & Product Group, Centocor, Inc., as Vice President & General Manager-Immunology from 1996 to 1999, KYORIN Pharmaceutical Co. Ltd. (old), as Principal, and Prometheus Laboratories, Inc., as President, Chief Executive & Operating Officer from 1999 to 2003. Mr. Schoeneck received his undergraduate degree in 1979 from Jacksonville State University.
-
- Kan Chen
- Kan Chen is currently a Non-Executive Director at Connect Biopharma Holdings Ltd. since 2020, LongBio Pharma (Suzhou) Co., Ltd. since 2025, and Ming Yu Pharmaceutical Ltd. since 2025. Former roles include Director at Jiangsu Yahong Meditech Co., Ltd. from 2020 to 2023, Non-Executive Director at Antengene Corp. Ltd. from 2021 to 2024, Non-Executive Director at Abbisko Cayman Ltd. from 2020 to 2021, and Non-Executive Director at CANbridge Pharmaceuticals Inc. from 2020 to 2024. Education includes a doctorate from Case Western Reserve University in 2009, an undergraduate degree from Fudan University in 2004, and a doctorate from Harvard Medical School in 2012.
-